JO3602B1 - مركبات بنزيميدازول بصفتها منظمات لمستقبلات في ار 1 - Google Patents

مركبات بنزيميدازول بصفتها منظمات لمستقبلات في ار 1

Info

Publication number
JO3602B1
JO3602B1 JOP/2007/0165A JOP20070165A JO3602B1 JO 3602 B1 JO3602 B1 JO 3602B1 JO P20070165 A JOP20070165 A JO P20070165A JO 3602 B1 JO3602 B1 JO 3602B1
Authority
JO
Jordan
Prior art keywords
benzimidazole
modulators
benzimidazole modulators
compounds
directed
Prior art date
Application number
JOP/2007/0165A
Other languages
English (en)
Inventor
Raul R Calvo Mr
William Parsons Mr
Kenneth M Wells Mr
Mark A Youngman Mr
Mark R Player Mr
Sharmila Patel Ms
Michael Brandt Mr
Wing S Cheunge Mr
Yu Kai Lee Mr
Michele C Jetter Mr
Wenxi Pan Mr
Scott L Dax Mr
Derek A Beauchamp Mr
Jian Liu Ms
Original Assignee
Janssen Pharmaceutica Nv
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Janssen Pharmaceutica Nv filed Critical Janssen Pharmaceutica Nv
Application granted granted Critical
Publication of JO3602B1 publication Critical patent/JO3602B1/ar

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/06—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D235/00—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, condensed with other rings
    • C07D235/02—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, condensed with other rings condensed with carbocyclic rings or ring systems
    • C07D235/04—Benzimidazoles; Hydrogenated benzimidazoles
    • C07D235/06—Benzimidazoles; Hydrogenated benzimidazoles with only hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, directly attached in position 2
    • C07D235/08—Radicals containing only hydrogen and carbon atoms
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/4164—1,3-Diazoles
    • A61K31/4184—1,3-Diazoles condensed with carbocyclic rings, e.g. benzimidazoles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/10—Drugs for disorders of the urinary system of the bladder
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/04—Centrally acting analgesics, e.g. opioids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/22—Anxiolytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/12—Antihypertensives
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
    • C07D403/06—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms

Abstract

يوجه الاختراع الى مركبات الصيغة (1) وتركيبات صيدلانية تحتوي على هذه المركبات وبطرق معالجة تستخدمها.
JOP/2007/0165A 2006-05-03 2007-04-25 مركبات بنزيميدازول بصفتها منظمات لمستقبلات في ار 1 JO3602B1 (ar)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US79750406P 2006-05-03 2006-05-03

Publications (1)

Publication Number Publication Date
JO3602B1 true JO3602B1 (ar) 2020-07-05

Family

ID=38566108

Family Applications (1)

Application Number Title Priority Date Filing Date
JOP/2007/0165A JO3602B1 (ar) 2006-05-03 2007-04-25 مركبات بنزيميدازول بصفتها منظمات لمستقبلات في ار 1

Country Status (37)

Country Link
US (3) US7951829B2 (ar)
EP (1) EP2021330B1 (ar)
JP (1) JP5302884B2 (ar)
KR (1) KR101434883B1 (ar)
CN (1) CN101511797B (ar)
AR (1) AR060840A1 (ar)
AT (1) ATE482201T1 (ar)
AU (1) AU2007248341C1 (ar)
BR (1) BRPI0709803B8 (ar)
CA (1) CA2651128C (ar)
CO (1) CO6160329A2 (ar)
CR (1) CR10479A (ar)
CY (1) CY1111269T1 (ar)
DE (1) DE602007009378D1 (ar)
DK (1) DK2021330T3 (ar)
EA (1) EA019386B1 (ar)
EC (1) ECSP088854A (ar)
ES (1) ES2350959T3 (ar)
HK (1) HK1131971A1 (ar)
HR (1) HRP20100700T1 (ar)
IL (1) IL194916A (ar)
JO (1) JO3602B1 (ar)
MX (1) MX2008014108A (ar)
MY (1) MY154595A (ar)
NI (1) NI200800290A (ar)
NO (1) NO341965B1 (ar)
NZ (1) NZ572251A (ar)
PE (1) PE20080065A1 (ar)
PL (1) PL2021330T3 (ar)
PT (1) PT2021330E (ar)
RS (1) RS51473B (ar)
SI (1) SI2021330T1 (ar)
TW (1) TWI419882B (ar)
UA (1) UA94749C2 (ar)
UY (1) UY30322A1 (ar)
WO (1) WO2007130780A2 (ar)
ZA (1) ZA200810234B (ar)

Families Citing this family (21)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
BRPI0721169A2 (pt) * 2006-12-15 2014-03-18 Janssen Pharmaceutica Nv Inibidores de benzimidazol trpv1
US20090092574A1 (en) 2006-12-29 2009-04-09 Scott Richard W Ophthalmic And Otic Compositions Of Facially Amphiphilic Polymers And Oligomers And Uses Thereof
JP5562865B2 (ja) * 2007-12-17 2014-07-30 ジヤンセン・フアーマシユーチカ・ナームローゼ・フエンノートシヤツプ Ｔｒｐｖ１のイミダゾロ−、オキサゾロ−、及びチアゾロピリミジン・モジュレーター
US20090156598A1 (en) * 2007-12-17 2009-06-18 Lebsack Alec D Imidazolopyrimidine modulators of TRPV1
MY152022A (en) * 2008-04-18 2014-08-15 Dae Woong Pharma A novel benzoxazine benzimidazole derivatives, a pharmaceutical composition comprising the same, and a use thereof
US8232409B2 (en) 2008-10-15 2012-07-31 Janssen Pharmaceutica N.V. Heterocyclic benzimidazoles as TRPM8 modulators
US8217060B2 (en) 2009-05-15 2012-07-10 Janssen Pharmaceutica, Nv Benzimidazole derivatives useful as TRP M8 receptor modulators
US8323805B2 (en) * 2009-06-04 2012-12-04 Nitto Denko Corporation Emissive aryl-heteroaryl acetylenes
CN102002010A (zh) * 2009-08-31 2011-04-06 住友化学株式会社 双噁唑啉基烷烃化合物的精制方法
DK2709619T3 (en) 2011-05-16 2018-01-15 Cellceutix Corp RELATIONSHIPS FOR USING THE TREATMENT OF MUCOSITIS
US9056874B2 (en) 2012-05-04 2015-06-16 Novartis Ag Complement pathway modulators and uses thereof
WO2014143638A1 (en) 2013-03-14 2014-09-18 Novartis Ag 2-(1h-indol-4-ylmethyl)-3h-imidazo[4,5-b]pyridine-6-carbonitrile derivatives as complement factor b inhibitors useful for the treatment of ophthalmic diseases
EA201690152A1 (ru) * 2013-07-11 2016-05-31 Бристол-Майерс Сквибб Компани Ингибиторы ido
WO2015066241A1 (en) 2013-10-30 2015-05-07 Novartis Ag 2-benzyl-benzimidazole complement factor b inhibitors and uses thereof
EP3348554B1 (en) * 2015-09-08 2020-05-06 Sumitomo Chemical Company, Limited Method for producing triazole compound
EP3534888B1 (en) * 2016-11-01 2022-04-06 Merck Sharp & Dohme Corp. Substituted bicyclic heteroaryl allosteric modulators of nicotinic acetylcholine receptors
US11512055B2 (en) * 2018-05-03 2022-11-29 Jiangsu Hengrui Medicine Co., Ltd. Benzimidazole derivatives as modulators of retinoid-related orphan receptor gamma (RORγ) and pharmaceutical uses thereof
CN108997398B (zh) * 2018-07-23 2020-12-15 被忽略疾病药物研发组织 一种3,3-二甲基苯并[c][1,2]氧杂戊硼烷-1(3h)-醇的制备方法
CN112745268B (zh) * 2019-10-31 2022-09-16 江苏恒瑞医药股份有限公司 苯并咪唑衍生物的晶型及制备方法
CA3156332A1 (en) * 2019-10-31 2021-05-06 Jiangsu Hengrui Medicine Co., Ltd. Acid addition salt of ror.gamma. regulator
WO2021248008A1 (en) 2020-06-05 2021-12-09 Innovation Pharmaceuticals Inc. Arylamide compounds for treatment and prevention of viral infections

Family Cites Families (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5612360A (en) * 1992-06-03 1997-03-18 Eli Lilly And Company Angiotensin II antagonists
US6299796B1 (en) 1997-12-18 2001-10-09 Fuji Photo Film Co., Ltd. Styryl compound, method for the preparation thereof and electroluminescent element employing the same
US6748803B1 (en) * 2000-02-22 2004-06-15 Simmonds Precison Products, Inc. Liquid measurement system and shared interface apparatus for use therein
PL377215A1 (pl) * 2002-10-17 2006-01-23 Amgen Inc. Pochodne benzimidazolu oraz ich zastosowanie w charakterze ligandów receptora waniloidowego
TW200418806A (en) * 2003-01-13 2004-10-01 Fujisawa Pharmaceutical Co HDAC inhibitor
US20050043379A1 (en) * 2003-07-28 2005-02-24 Axe Frank U. LTA4H Modulators
JP2007521325A (ja) * 2003-10-28 2007-08-02 バーテックス　ファーマシューティカルズ　インコーポレイテッド イオンチャネルのモジュレーターとして有用なベンズイミダゾール
WO2006058338A2 (en) * 2004-11-29 2006-06-01 Janssen Pharmaceutica N.V. 4 - piperidinecarboxamide derivatives as modulators of vanilloid vr1 receptor
CA2654246A1 (en) * 2006-07-04 2008-01-10 Janssen Pharmaceutica N.V. Benzimidazole cannabinoid agonists bearing a substituted heterocyclic group
BRPI0721169A2 (pt) * 2006-12-15 2014-03-18 Janssen Pharmaceutica Nv Inibidores de benzimidazol trpv1

Also Published As

Publication number Publication date
JP5302884B2 (ja) 2013-10-02
KR20090008428A (ko) 2009-01-21
BRPI0709803B1 (pt) 2019-12-10
NZ572251A (en) 2010-08-27
US20110190364A1 (en) 2011-08-04
EA019386B1 (ru) 2014-03-31
PE20080065A1 (es) 2008-02-25
DK2021330T3 (da) 2010-12-06
WO2007130780A3 (en) 2008-02-14
CY1111269T1 (el) 2015-08-05
BRPI0709803B8 (pt) 2021-05-25
TWI419882B (zh) 2013-12-21
PT2021330E (pt) 2010-12-03
MY154595A (en) 2015-06-30
CN101511797B (zh) 2013-01-02
US7951829B2 (en) 2011-05-31
PL2021330T3 (pl) 2011-03-31
EA200870497A1 (ru) 2009-06-30
UY30322A1 (es) 2007-08-31
US20110190344A1 (en) 2011-08-04
ECSP088854A (es) 2008-11-27
IL194916A (en) 2013-01-31
AU2007248341A1 (en) 2007-11-15
NO20085031L (no) 2009-01-06
EP2021330A2 (en) 2009-02-11
BRPI0709803A2 (pt) 2011-07-26
SI2021330T1 (sl) 2011-01-31
DE602007009378D1 (de) 2010-11-04
CN101511797A (zh) 2009-08-19
NI200800290A (es) 2012-01-30
EP2021330B1 (en) 2010-09-22
ATE482201T1 (de) 2010-10-15
CR10479A (es) 2009-03-31
AR060840A1 (es) 2008-07-16
CA2651128C (en) 2014-09-02
UA94749C2 (en) 2011-06-10
WO2007130780A2 (en) 2007-11-15
NO341965B1 (no) 2018-03-05
IL194916A0 (en) 2009-08-03
TW200808738A (en) 2008-02-16
ZA200810234B (en) 2010-02-24
MX2008014108A (es) 2008-11-14
CA2651128A1 (en) 2007-11-15
AU2007248341C1 (en) 2013-01-17
KR101434883B1 (ko) 2014-08-27
HRP20100700T1 (hr) 2011-02-28
ES2350959T3 (es) 2011-01-28
US20070259936A1 (en) 2007-11-08
JP2009535414A (ja) 2009-10-01
RS51473B (en) 2011-04-30
CO6160329A2 (es) 2010-05-20
AU2007248341B2 (en) 2011-12-08
HK1131971A1 (en) 2010-02-12

Similar Documents

Publication Publication Date Title
JO3602B1 (ar) مركبات بنزيميدازول بصفتها منظمات لمستقبلات في ار 1
MX2009005462A (es) Analogos de 7,8-saturados-4,5-epoxi-morfinano.
TW200716606A (en) Chemical compounds
TW200800963A (en) Chemical compounds
HK1113352A1 (en) Chemical compounds
HK1114375A1 (en) Chemical compounds
MX2009003080A (es) Compuestos organicos heterociclicos.
MY153263A (en) Heterocyclic compounds suitable for the treatment of diseases related to elevated lipid levels
TW200833326A (en) Chemical compounds 572
SG10201809390QA (en) Modulators of indoleamine 2,3-dioxygenase and methods of using the same
EP2091328A4 (en) SPIROPIPERIDININHIBITORS OF BETA-SECRETASE FOR THE TREATMENT OF ALZHEIMER DISEASE
MX2009006473A (es) Inhibidores de receptor vainilloide de bencimidazol.
TW200716134A (en) Tricyclic opioid modulators
UA96785C2 (uk) Заміщені похідні оксиндолу та їх застосування як лігандів рецептора вазопресину
SG158091A1 (en) Imidazoazepinone compounds
UA106200C2 (uk) Заміщені похідні оксіндолу та їхнє застосування для лікування захворювань, залежних від вазопресину
DE602007007934D1 (en) Imidazoazephinonverbindungen
TW200738244A (en) 20-Alkyl, gemini vitamin D3 compounds and methods of use thereof
EP2073635A4 (en) MACROCYCLIC SPIROPIPERIDINE BETA SEKRETASE INHIBITORS FOR THE TREATMENT OF MORBUS ALZHEIMER
TW200603801A (en) Novel dialkoxy-imidazopyridines
MX2007004535A (es) Antagonistas de integrinas bifenilicos.
UA96295C2 (en) Antiviral phosphinate compounds